Screening of open-source libraries from the Medicines for Malaria Venture using Bunyamwera virus as a model reveals inhibitors of Oropouche virus infection
Journal of General Virology · 12.11.2026 · 107 (11)
DOI: 10.1099/jgv.0.002356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of General Virology, erschienen am 12.11.2026. Verfasst von Natasha M. Cassani und 5 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Medical Research Council.
Abstract (Originalsprache)
Arboviral infections remain a major public health concern in tropical and subtropical regions, where environmental and socioeconomic conditions facilitate the circulation of diverse RNA viruses, including over 350 members of the recently renamed Peribunyaviridae family. In this regard, Oropouche virus (OROV) has caused explosive outbreaks in the Amazon region and shows wider distribution in Brazil, with confirmed neurological infections and fatalities in 2024. The absence of effective antiviral therapies highlights an urgent need for the discovery of anti-OROV drugs. In this work, we evaluated the antiviral potential of the Pandemic Response Box and Global Health Priority Box libraries from the Medicines for Malaria Venture (MMV) against OROV, using a well-established Bunyamwera virus (BUNV) system, widely used as a prototype of the Peribunyaviridae family, expressing the reporter gene enhanced green fluorescent protein ( eGFP) . A screening protocol based on fluorescent reporter gene detection by live cell imaging was employed. Nine compounds were identified with significant activity against BUNV- eGFP , with three being highlighted as the most promising hits: Trimetrexate, GSK-983 and MMV1634385. These compounds were validated by testing for activity against OROV, and in these assays, GSK-983 exhibited the lowest EC 50 value and consequently the highest selectivity index. Future studies should evaluate the antiviral efficacy of GSK-983 and assess its pharmacokinetic profile. Furthermore, our results indicate that our approach employing BUNV- eGFP as a model against OROV provides an efficient route to prioritize candidate compounds from large libraries, thereby establishing a practical screening route for future antivirals against Oropouche fever.
Förderung
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Medical Research Council
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Biotechnology and Biological Sciences Research Council
Zitieren
APA
Cassani, N. M., Pearson, H. M., Barr, J. N., Rahal, P., Harris, M., & Jardim, A. C. G. (2026). Screening of open-source libraries from the Medicines for Malaria Venture using Bunyamwera virus as a model reveals inhibitors of Oropouche virus infection. Journal of General Virology, 107(11). https://doi.org/10.1099/jgv.0.002356
Vancouver
Cassani NM, Pearson HM, Barr JN, Rahal P, Harris M, Jardim ACG. Screening of open-source libraries from the Medicines for Malaria Venture using Bunyamwera virus as a model reveals inhibitors of Oropouche virus infection. Journal of General Virology. 2026;107(11). doi:10.1099/jgv.0.002356
BibTeX
@article{Cassani2026,
author = {Cassani, Natasha M. and Pearson, Hayley M. and Barr, John N. and Rahal, Paula and Harris, Mark and Jardim, Ana Carolina Gomes},
title = {Screening of open-source libraries from the Medicines for Malaria Venture using Bunyamwera virus as a model reveals inhibitors of Oropouche virus infection},
journal = {Journal of General Virology},
year = {2026},
volume = {107},
number = {11},
doi = {10.1099/jgv.0.002356}
}
EUVIMED